Clinical trial
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After…
NCT00318370 · Morphotek, Industry · Completed
Key facts
| NCT number | NCT00318370 |
|---|---|
| Title | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy |
| Official title | A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse |
| Lead sponsor | Morphotek, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms |
| Intervention type | Drug |
| Interventions | Farletuzumab, Chemo Plus Far |
| Enrollment | 58 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Apr 26, 2006 |
| Last update posted | Sep 9, 2015 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: